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access article under the CC BY-NC-NDSummary Background/objective: The impact of medications with anti-cholinergic proper-
ties on morbidity and mortality of unselected adult patients admitted to the emergency gen-
eral surgical setting has not been investigated.
Methods: All cases were identified prospectively from unselected adult patients admitted to
the emergency general surgical ward between May to July 2016 in a UK centre with a catch-
ment population circa 500,000. Prescribed medication lists were ascertained from case notes
and electronic medical records. Anti-Cholinergic Burden (ACB) was calculated from medication
lists. Patients were categorised into three groups based on ACB; none (ACB score of 0); mod-
erate (up to ACB score of two); high (ACB score more than two). The effect of increasing ACB
on selected outcomes of 30- and 90-day mortality, hospital readmission within 30-days of
discharge and increased length of hospital stay were examined using multivariable logistic
regression models.
Results: The 452 patients had a mean age (SD) of 51.7 (20.6) years, 273 (60.4%) patients had
no ACB burden, 106 (23.5%) had a ACB burden of up to two; and 73 (16.2%) had an ACB burden
of > 2. Multivariable analyses showed no association between high ACB burden and 90-dayof Geriatric Medicine, 3rd Floor Academic Centre, Llandough Hospital, Penlan Road, Penarth, CF64
c.uk (J. Hewitt).
.10.005
ciation and Taiwan Robotic Surgery Association. Publishing services by Elsevier B.V. This is an open
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
528 A.D. Ablett et al.(fully adjusted odds ratio [OR] 0.56 (95%CI 0.12e2.85); P Z 0.48) and 30-day mortality (fully
adjusted ORZ 0.75 (95%CI 0.05e11.04); PZ 0.84). A significant association was observed be-
tween moderate ACB burden and 30-day hospital readmission (fully adjusted ORZ 2.01 (95%CI
1.09e3.71); P Z 0.03).
Conclusions: Anti-cholinergic burden may be linked to hospital readmission in adults admitted
to an emergency general surgical ward.
ª 2018 Asian Surgical Association and Taiwan Robotic Surgery Association. Publishing services
by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
The adverse effects associated with anti-cholinergic medi-
cation use have been well documented in older adults aged
65 and over in the medical and elective surgical settings.1e4
Previous studies have reported the prevalence of anti-
cholinergic use to be as high as 50% in older adults in the
community, however, its prevalence in unselected acutely
ill general surgical adults is unclear.4,5 Medications with
anti-cholinergic properties are used to treat many chronic
conditions, including gastrointestinal diseases such as
excessive gastric acid and intestinal motility disorders.6
Through competitively binding to central and peripheral
muscarinic receptors, anti-cholinergic medications act
through inhibiting the effects of the neurotransmitter
acetylcholine (Ach), resulting in the relatively high side-
effect profile.7 The commoner side-effects of anticholin-
ergic medications include constipation, dry mouth, dry
eyes, urinary retention, falls and confusion.8 The culminate
effect of taking multiple anti-cholinergic medications can
be estimated by the anti-cholinergic burden, which can be
measured using tools such as the Anti-Cholinergic Burden
Scale (ACB).9e11 The ACB is the most validated expert based
anti-cholinergic scale on adverse anti-cholinergic out-
comes.9 In patients who undergo abdominal surgery, studies
have reported an association between anti-cholinergic
medication use and post-operative complications such as
paralytic ileus.3
However, more serious adverse effects have also been
reported in older adults, such as mortality. In a meta-
analysis of 11 studies, Ruxton and colleagues reported an
association between having an ACB score and all-cause
mortality (fully adjusted OR (95% CI) Z 2.06 (95%CI
1.82e2.33), with a 106% increase in mortality for each
additional point added to a patient’s ACB in older adults.2
Earlier studies have primarily focused on the effect of
ACB in older adults, however, the potentially high preva-
lence of anti-cholinergic medication use in emergency
surgical admissions, coupled with the high adverse effect
profile of ACB, makes the investigation of ACB on acutely ill
general surgical patients a pertinent issue. Consequently,
we aim to investigate the association between having an
ACB burden and clinical outcomes including: mortality;
readmission; and length of stay.
2. Material/patients and methods
As part of the Older Persons Surgical Outcomes Collabora-
tion (OPSOC) http://www.opsoc.eu, this prospectivecohort study was conducted in Aberdeen Royal Infirmary,
a tertiary referral centre for general surgery serving
approximately half a million residents of North East of
Scotland. In line with OPSOC methodology previously
described, data were collected within the acute general
surgical admissions setting for all patients consecutively
admitted to the emergency general surgical ward
throughout May to July 2016 and patients were followed
for three months.12
Patients were excluded if they presented with the
following conditions: vascular, urological, trauma and or-
thopaedics and neurological surgical emergencies, as they
would have been admitted under specialist surgical teams.
No other inclusion or exclusion criteria were used and data
were collected for consecutive acute surgical admissions
during the study period. Patients admitted to the acute
general surgical setting in the UK vary in their presenting
pathology. Most admissions relate to the gastrointestinal
system i.e. appendicitis, diverticulitis, bowel obstruction or
pancreato-biliary disease, but may also include minor sur-
gical condition such as abscesses, and non-specific
abdominal pain. In the UK, all patients admitted to the
emergency general surgical department remain under the
care of the general surgical team, regardless of whether
they receieve an emergency surgical procedure. Patients
with surgically related problems admitted under medical
teams with outreach surgical team input or patients
managed conservatively under the care of medical teams
were not included.3. Outcomes
The primary outcome was the relationship between ACB
and mortality at 90- and 30-days. The secondary outcomes
were ACB and readmission within 30-day post-discharge,
and increased hospital length of stay.4. Data collection
Data were recorded and stored in conjunction with local
data management standard operating procedures. This
study was deemed a service evaluation and did not require
ethical approval. Only audit registration and approval
within the Aberdeen Royal Infirmary was required and
granted. Medications on admission were collected in one
OPSOC site (Aberdeen Royal Infirmary) during the 2016
audit cycle with the view of assessing the link between ACB
and patient related outcomes.
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shown in the Supplementary Table 1), each medication was
assigned an ACB score and the total ACB burden was
calculated for each patient as described by Myint et al. 10,13
In addition to the established anti-cholinergic medications,
we also classed Prochlorperazine (or Chlorperazine) and
Procyclidine as scoring 3 after consultation with opinion
leaders in the field. Each patient’s total score was cat-
egorised into one of the three groups depending on the sum
of their total ACB score (none (ACB Z 0); moderate
(ACB Z 1e2), high (ACB  3)) (see Supplementary Table 1
for the scoring system).
To characterise co-morbidity, we recorded baseline
characteristics, recorded categorically, for the following;
anaemia (Hb < 129 g/L), hypoalbuminaemia (albumin
<35 g/L) and polypharmacy (5 medications on admission).
Frailty was assessed using the seven-point Canadian Study
on Health and Aging (CSHA) Clinical Frailty Scale
(Supplementary Table 2).
All cases were prospectively identified and baseline
data assessed on admission. Follow-up data were obtained
via in-hospital electronic records at a later date. A
continuous value was recorded, for the length of hospital
stay (LOS), with days rounded up to the nearest whole day
integer. The LOS was arbitrarily re-categorised for ease of
interpretation for clinicians, into three dichotomised
variables <7 and 7-days, <10 days and 10-days and <14
days and 14-day, which corresponded approximately
with the 80th, 90st and 95th centile values of the LOS.
Readmission within 30 day, mortality at 30- and 90-days
were also collected. Following the standard definition
for multi-morbidity throughout the literature, we defined
multi-morbidity as the presence of 2 co-morbidies. We
only specifically recorded the presence of co-morbidies
such as DM, cardiac failure and dementia as they form
the Charlson Co-morbidity Index, which have been shown
to be an accurate predictor of poor outcomes such as one-
year mortality.14 The variables were selected on the basis
that they are known predictors of surgical outcomes and
grouped into four models in order to allow for observation
of how related characteristics, when adjusted for, influ-
enced our measured outcomes.Figure 1 Flow chart describing reasons for exclusion.5. Statistical analysis
All analyses were performed using Statistical Package for
Social Science (SPSS), version 24.0. Characteristics were
compared by ACB category using ANOVA and Chi-squared test
for continuous and categorical data respectively. Logistic
regression models were constructed to examine the associa-
tion between ACB as the predictor variable (with ACB score of
0 as the reference category) and dichotomised outcomes. In
all logistic regression models, we conducted unadjusted data
(model A), andmade additional adjustments for age, sex, and
admission from home (model B), with further incremental
adjustment for receipt of an emergency operation, low al-
bumin, low haemoglobin, high CRP, low eGFR (model C), and
finally we adjusted for the frailty scale (model D). No formal
sample size calculation was carried out due to the nature of
the observational study design.6. Results
Data were collected from 500 unselected adults admitted
to the emergency surgical ward, with 48 patients excluded
due to incomplete data, leaving a cohort of 452 patients
(see Fig. 1). Almost a third of patients underwent an
emergency operation (32.5%), with 44% of patients who
received an emergency operation taking medications with
anti-cholinergic properties. The characteristics of the
sample by categories of total ACB (score 0, score 1e2, score
3) are presented in Table 1. Of 452 patients, 39.6% (179)
were taking anti-cholinergic medications, while 60.4% (273)
had ACB score 0, 23.5% (106) had ACB score 1e2, and 16.2%
(73) had ACB score 3. When focussing only on adults aged
65, the prevalence of anti-cholinergic use was 53.8%. ACB
scores ranged from 0 to 10 with the mean ACB score (SD) of
our cohort being 0.97 (1.6). The mean age (SD) was 51.7
(20.6) years. Increase in age, multi-morbidity, poly-
pharmacy and emergency operations were observed with
increasing ACB score, whereas albumin, eGFR and haemo-
globin levels decreased with increasing ACB.
39.2% (177) were male and 60.8% (275) were female,
with a greater proportion of female patients with higher
ACB scores. Using the frailty scale, the highest proportion
of adults with ACB score 1e2 were “well.” Meanwhile, the
greatest proportion of adults with ACB score 3 were “well
with treated co-morbid disease.”
We found that the number of co-morbid diseases a pa-
tient had correlated significantly with higher ACB scores
(Fig. 2). In the fully adjusted multivariate model, we found
no association between ACB score 1e2 (1.30 (0.37e4.56); P
Z 0.69) or ACB score of 3 (0.56 (0.12e2.85); P Z 0.48)
compared to those with ACB score of 0 with regard to the
primary outcome of 90-day mortality (Table 2). We similarly
found no association between ACB and 30-day mortality.
Table 1 Patients’ characteristics by anti-cholinergic burden score on admission (N Z 452).
ACB score 0
N Z 273 (60.4%)
ACB score 1e2
N Z 106 (23.5%)
ACB score 3
N Z 73 (16.2%)
P
Characteristics
Age (years) 46.87 (20.13) 61.31 (19.16) 55.73 (18.42) <0.001
Sex 0.002
Male 119 (44) 43 (41) 15 (21)
Female 154 (56) 63 (59) 58 (79)
Admitted from home 267 (98) 101 (95) 67 (92) 0.047
Hypoalbuminaemia (g/l) 88 (32) 60 (57) 39 (53) <0.001
Anaemia (g/l) 87 (32) 56 (53) 39 (53) <0.001
eGFR60 (mL/min/1.73 m2) 24 (9) 22 (21) 12 (16) 0.005
CRP 0.74
<10 123 (45) 42 (40) 27 (37)
10e50 75 (27) 32 (30) 23 (32)
>50 75 (27) 32 (30) 23 (32)
Multimorbidity (2) 49 (18) 49 (46) 38 (52) <0.001
Diabetes 17 (6) 9 (8) 16 (22) <0.001
Dementia 6 (2) 4 (4) 3 (4) 0.56
Congestive cardiac failure 2 (1) 7 (7) 1 (1) 0.002
History of Falls 13 (5) 12 (11) 7 (10) 0.054
Depression 60 (22) 30 (28) 21 (29) 0.29
Visual Impairment 11 (4) 7 (7) 6 (8) 0.29
Hearing Impairment 21 (8) 18 (17) 4 (5) 0.01
Urinary Incontinence 1 (0) 5 (5) 5 (7) 0.001
Frailty Scale <0.001
Very Fit 135 (49) 14 (13) 13 (18)
Well 63 (23) 35 (33) 16 (22)
Well with Treated Co-morbidities 44 (16) 24 (23) 23 (32)
Apparently Vulnerable 22 (8) 21 (20) 11 (15)
Mildly Frail 6 (2) 11 (10) 6 (8)
Moderately Frail 2 (1) 1 (1) 4 (5)
Severely Frail 1 (0) 0 (0) 0 (0)
Polypharmacy 59 (22) 71 (67) 51 (70) <0.001
Operation 106 (39) 27 (25) 14 (19) 0.001
Mortality at 90 days 6 (2) 7 (7) 3 (4) 0.11
Mortality at 30 days 4 (1) 3 (3) 3 (4) 0.35
Readmitted at 30 days 40 (15) 27 (25) 11 (15) 0.038
Length of Stay
7 or more days 50 (18) 28 (26) 12 (16) 0.15
10 or more days 32 (12) 12 (11) 8 (11) 0.98
14 or more days 15 (5) 5 (5) 5 (7) 0.83
Bold values are statistically significant; p <0.05.
Values presented are mean (SD) for continuous data and number (%) for categorical data. P values were generated using a one-way
ANOVA test for continuous variables and a chi square test for categorical variables.
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univariate (1.99 (1.15e3.45); P Z 0.01) and fully adjusted
logistic regression models (2.01 (1.09e3.71); P Z 0.025).
However, this association was lost in those with higher ACB
scores (3). Our multivariate model showed no association
between ACB and an increased length of hospital stay or a
change in destination from home to not home (Table 3).7. Discussion
Anti-cholinergic medication use is prevalent in emergency
general surgical admissions with almost 40% of our cohortusing at least one medication with anti-cholinergic prop-
erties. Patients with a greater co-morbidity burden were
directly and positively associated with higher ACB. We
found no association between ACB and mortality, length of
hospital stay, or discharge destination of adult patients.
However, a moderate ACB burden was associated with 30-
day readmission. No association was found between ACB
and readmission in those with the greatest ACB burden.
The existing literature on the association between ACB
and outcomes focuses almost exclusively on older adults in
community or medical settings. To the best of our knowl-
edge, we are the first to report the prevalence of anti-
cholinergic medication use in unselected adult patients
Figure 2 Comparing mean anti-cholinergic burden score with number of co-morbidities.
Table 2 Results of logistic regression analysis examining
the association between anti-cholinergic burden (reference
category Z 0) and 90-day mortality, 30-day mortality and
30-day readmission.
Models ACB 1e2 (N Z 106) ACB 3 (N Z 73)
OR 95% CI P OR 95% CI P
90-Day Mortality
A 3.15 1.03e9.59 0.044 1.91 0.47e7.82 0.37
B 1.85 0.57e5.99 0.30 1.28 0.29e5.63 0.74
C 1.45 0.42e4.96 0.55 0.82 0.18e3.80 0.80
D 1.30 0.37e4.56 0.69 0.56 0.12e2.85 0.48
30-Day Mortality
A 1.96 0.43e8.90 0.38 2.88 0.63e13.18 0.17
B 0.84 0.17e4.17 0.84 2.54 0.45e14.17 0.29
C 0.62 0.06e6.67 0.69 1.33 0.13e13.38 0.81
D 0.56 0.04e7.18 0.65 0.75 0.05e11.04 0.84
30-Day Readmission
A 1.99 1.15e3.45 0.014 1.03 0.50e2.13 0.93
B 2.24 1.25e4.02 0.007 1.11 0.53e2.34 0.78
C 2.15 1.17e3.93 0.013 1.12 0.52e2.36 0.79
D 2.01 1.09e3.71 0.025 0.99 0.46e2.16 0.99
Bold values are statistically significant; p <0.05.
Model A: Unadjusted.
Model B: Age, Sex, Admitted from Home.
Model C: B þ Operation, Hypoalbuminemia, Low Haemoglobin,
CRP, eGFR.
Model D: C þ Frailty scale.
Table 3 Results of logistic regression analysis examining
the association between anti-cholinergic burden (reference
category Z 0) and length of stay (LOS); 7 days or more, 10
days or more, 14 days or more and change in destination
from home to not home.
Models ACB 1e2 (N Z 106) ACB 3 (N Z 73)
OR 95% CI P OR 95% CI P
LOS; 7 days or more
A 1.60 0.94e2.72 0.08 0.88 0.44e1.75 0.71
B 1.04 0.59e1.86 0.89 0.60 0.28e1.28 0.19
C 1.19 0.62e2.28 0.60 0.64 0.28e1.49 0.30
D 1.14 0.59e2.20 0.69 0.60 0.26e1.41 0.24
LOS; 10 days or more
A 0.96 0.48e1.95 0.91 0.93 0.41e2.11 0.86
B 0.58 0.27e1.26 0.17 0.59 0.24e1.47 0.26
C 0.61 0.26e1.42 0.25 0.64 0.24e1.70 0.37
D 0.60 0.25e1.39 0.23 0.61 0.23e1.65 0.33
LOS; 14 days or more
A 0.85 0.30e2.40 0.76 1.27 0.44e3.60 0.66
B 0.44 0.14e1.33 0.14 0.96 0.31e3.00 0.95
C 0.44 0.13e1.54 0.20 1.28 0.37e4.43 0.69
D 0.44 0.13e1.52 0.19 1.20 0.34e4.27 0.77
Change in Destination from Home to not Home
A 0.86 0.17e4.31 0.85 1.25 0.25e6.34 0.79
B 0.38 0.07e2.14 0.27 1.72 0.28e10.73 0.56
C 0.45 0.07e3.00 0.41 1.84 0.26e12.87 0.54
D 0.46 0.07e3.15 0.43 1.72 0.23e12.67 0.59
Model A: Unadjusted.
Model B: Age, Sex, Admitted from Home.
Model C: B þ Operation, Hypoalbuminemia, Low Haemoglobin,
CRP, eGFR.
Model D: C þ Frailty scale.
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previous reports from 2009 have estimated the prevalence
of anti-cholinergic medication use in only older adults in
the community setting to be as high as 50%, our study found
that the prevalence of anti-cholinergic use in unselected
adults in emergency general surgical admissions to be
almost 40%.4 This may suggest that anti-cholinergic medi-
cation use is on the rise which is likely a consequence ofincreasing life expectancy and management of more com-
plex patients living with a combination of co-morbid dis-
eases.15 This is supported by our findings (Fig. 2) which
532 A.D. Ablett et al.show that the average ACB a patient had, positively
correlated with the number of co-morbidities they were
living with. Subsequently, as the use of anti-cholinergic
medication may continue to rise, better understanding of
their impact on surgical outcomes requires further
investigations.
We observed that patients with a high ACB were less
likely to undergo an emergency operation (Table 1).
Consequently, in order to identify whether this finding was
due to more co-morbidities in high ACB patients, we
compared receipt of an emergency operation in moderate
ACB and high ACB patients with increasing co-morbidities
(Fig. 3). Our findings show that patients with high ACB
and no co-morbidities were less likely to require an emer-
gency operation than patients with high ACB and the
presence of co-morbidities. This is likely due to patients
taking medications to treat a non-surgical condition e.g.
medications used to treat a patient with an overactive
bladder are likely to score highly in ACB, yet such patients
may not require an emergency operation for a gastroin-
testinal related condition.
We found no association between ACB and mortality. In a
large cohort study of 21,636 community dwelling partici-
pants, aged between 40 and 79 years of age, Myint and
colleagues observed that higher ACB scores were associated
with mortality, with a mean follow up of 14.9 years.13
Similarly, Fox and colleagues found an association be-
tween ACB and mortality at 2 years, 12, 423 participants.16
Subsequently, our cohort consisted of only 452 patients and
studies which have found an association between ACB and
mortality tend to have a larger cohort, thus our study is
likely to be underpowered.12,16e18 However, given the
observational nature of our study, a formal power analysis
was not appropriate. Earlier studies have reported the
relative deterioration of the central cholinergic system as a
consequence of the aging process which increases the
sensitivity of older patients to blockade of muscarinic re-
ceptors.11,19 Therefore, it may be the case that ACB is only
associated with mortality in older patients resulting from
the combination of older people tending to have higher ACBFigure 3 The proportion of patients undergoing an emergency opscores, which we have shown to be positively correlated
with co-morbidities, whilst also having a greater sensitivity
to anti-cholinergics due to the deterioration of their
cholinergic system. Nevertheless, in a systematic review of
nine studies, most of the studies found no association be-
tween anti-cholinergics and mortality, however, Fox and
colleagues concluded that the association was inconclusive,
as a number of the studies had inadequate follow -up
periods.7,20,21
Increased length of hospital stay and hospital read-
missions are not only associated with poor patient out-
comes, but they are also costly and resource
consuming.22,23 Although, previous studies have found an
association between ACB and increased length of hospital
stay in older patients, our study found no association be-
tween ACB and increased length of stay in adults, which is
likely due to the relatively young age of our cohort.24,25
Nevertheless, at moderate ACB scores (1e2), we
observed an association between ACB and 30-day hospital
readmission. This finding is consistent with earlier reports
which focused on the association between ACB and 30-day
readmission in older adults, however we are the first to
report this association in adults.26,27 Nonetheless, this as-
sociation was lost with a higher ACB score. This may be
explained by the fact that patients with higher ACB tended
to be older persons and likely to have healthcare arrange-
ments which accommodate for the management of these
patients in the community. Meanwhile, patients with a
lower ACB tend to be younger therefore may not have such
arrangements in place, thereby resulting in increased
likelihood of 30-day hospital readmission.
Our study has a number of limitations. Firstly, as a result
of the non-randomised study design, caution ought to be
used when interpreting our findings. The follow -up period
for measurement of mortality was only 90-days and may not
be long enough to capture morality association with
increased ACB burden. We did not have data on perioper-
ative complications and therefore we were unable to
observe any potential association between ACB and peri-
operative complications. Furthermore, we did not haveeration comparing ACB category with increasing co-morbidities.
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we were unable to assess whether readmission could be
explained by ACB. We recognise that a separate analysis
including only patients who underwent an emergency
operation would have been useful, due to relatively smaller
sample receiving an emergent operation (n Z 147), we
decided not to conduct such analysis as this could poten-
tially lead to type II error. While we were able to control for
some markers of severity of acute illness such as anaemia,
hypalbuminaemia and C-reactive protein level, since pa-
tients admitted in emergency setting are often complicated
with Systemic Inflammatory Response Syndrome (SIRS) re-
actions, future work should include the use of clinical
scores such as the Quick Sepsis Related Organ Failure
Assessment (qSOFA) in their analysis in order to adequately
accounted for sepsis.
Meanwhile, strengths of our paper include the use of a
detailed and accurate medication lists extracted from
electronic medical records. Additionally, patient data was
collected for all consecutive adult admissions to the gen-
eral surgical ward without selection. It is foreseeable that
the patients who underwent an operation may be exposed
to higher anti-cholinergic burden and future investigations
should also focus on this patient population.
In conclusion, anti-cholinergic medication use is preva-
lent in unselected adult patients admitted to the emer-
gency general surgical setting, with almost 40% of patients
being prescribed at least one anti-cholinergic medication.
We observed that whilst patients with a high ACB were less
likely to receive an emergency operation, patients with a
moderate ACB were associated with 30-day hospital read-
mission. We encourage further research into the association
between anti-cholinergic medication use and outcomes in
emergency surgical admissions perhaps focusing on older
people and those who undergo operation.Conflicts of interest
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